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Current therapies for acute kidney injury remain primarily
supportive and have failed to reduce morbidity, mortality
(450%), and associated costs. This prompted our studies
in which rats with bilateral ischemia/reperfusion-induced
acute kidney injury were treated with bone marrow-derived,
culture-expanded allogeneic mesenchymal stem cells.
Their administration into the suprarenal aorta after reflow
significantly protected renal function and hastened repair,
mediated by complex antiapoptotic, mitogenic, anti-
inflammatory, and immune modulating actions that were not
elicited by isogeneic fibroblasts. Infused mesenchymal stem
cells, recruited to renal sites of injury, did not significantly
differentiate into target cells but rather disappeared from
kidneys and other organs within 72h. Furthermore, at
3 months, compared with vehicle-treated controls, renal
function was well preserved and interstitial fibrosis was
absent. These preclinical data served as the scientific
basis for a recently completed Phase I Clinical Trial
(http://www.clinicaltrials.gov; # NCT00733876), in which
patients at high risk for cardiac surgery-associated AKI were
treated with allogeneic mesenchymal stem cells. Until now,
MSC therapy in the study subjects has been safe, and
none of the patients has developed postoperative AKI
or subsequent loss of renal function, suggesting that this
novel form of therapy may have promise in this group
of high-risk patients, which will be further investigated
in a Phase II Trial.
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Until now, no definitively effective treatment for the preven-
tion of clinical acute renal failure or improved repair post-
acute kidney injury (AKI) has been developed. Such effective
therapy is, however, urgently needed because significant acute
renal failure is associated with high morbidity and mortality
rates, and substantial costs for required medical care.1
Importantly, even when renal function appears to fully recover
after AKI, it is now recognized that a significant proportion of
patients develop end-stage renal disease as a consequence of
undiagnosed, incompletely resolved, or untreated AKI. This
form of chronic kidney disease is characterized by continued
inflammatory and fibrotic processes, and microvascular
rarefaction.2 Consequently, those patients who seemingly
recover from AKI frequently go on to develop chronic kidney
disease, a significant percentage of these eventually requiring
chronic hemodialysis or a renal transplant.2,3
This continued therapeutic dilemma of AKI prompted us
and others to investigate the potential therapeutic utility of
adult bone marrow-derived mesenchymal stem cells, also
termed multipotent stromal cells (MSCs).4–9 Physiologically,
these cells can differentiate into various mesenchymal cell
types and support hematopoietic stem cells in the bone
marrow niches. They are found in a pericyte location in all
adult organs, as well as in adipose tissue and umbilical cord
blood and tissue.10 MSCs can be readily obtained from the
bone marrow and culture expanded. They differentiate into
mesenchymal cell types (fat, bone, cartilage), do not express
HLA-II (DR) and blood-group antigens, and secrete a large
number of growth factors such as vascular endothelial growth
factor, hepatocyte growth factor, insulin-like growth factor-I,
and others.9,11–13 Until now, MSCs have been safely and
effectively used to treat children with osteogenesis imperfecta,
patients with graft-versus-host disease, Crohn’s disease,
Hurler syndrome, poor bone marrow engraftment, poorly
healing fractures, myocardial infarction, and other indica-
tions (http://www.clinicaltrials.org).14 In addition, a large
number of preclinical studies have proven their therapeutic
potential in models of the above diseases.
On the basis of this background, we hypothesized that the
delivery of MSCs to rat kidneys with ischemia/reperfusion-
induced AKI would favorably alter the subsequent outcome
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through their potential ability to differentiate into and
replace destroyed renal cells. Our data demonstrated, how-
ever, that administered MSCs only temporarily reside in the
injured kidneys, and that they function renoprotectively
through paracrine antiapoptotic, mitogenic, anti-inflamma-
tory, and immune modulating effects.6 We used the consis-
tently positive results with this form of cell therapy as the
scientific justification for a recently completed Phase I
Clinical Trial in patients at particularly high risk for the
development of AKI following on-pump cardiac surgery; that
is, patients with underlying renal disease, diabetes mellitus,
older age, congestive heart failure, hypertension, and chronic
obstructive pulmonary disease.15–17
PRECLINICAL STUDIES: TREATMENT OF AKI WITH
ALLOGENEIC MSCs
On the basis reports by several other investigators, the
administration of MSCs, hematopoietic stem cells, or a bone
marrow transplant, following myeloablation, to rodents with
glycerol-, cis-platinum-, or ischemia/reperfusion-induced
AKI, protected renal function and improved recovery,
mediated, as was concluded, by significant engraftment of
stem cells that had differentiated into tubular cells.4,5,18,19
However, as differentiation of MSCs into renal cells requires
several days, we questioned whether the prompt renoprotec-
tive effects of these cells, clearly observed by 12–24 h post-
infusion and ischemic injury, was indeed the result of cell
differentiation and engraftment. To investigate this issue
further, we conducted a series of preclinical studies that
are summarized in the following, and that formed the
basis for a now completed Phase I Clinical Trial (http://
www.clinicaltrials.gov; # NCT00733876). We tested whether
the immediate or delayed administration, by 24 h, of
syngeneic or allogeneic MSCs to rats with ischemia/reperfu-
sion-induced AKI was safe and exerted significant renopro-
tective and repair-stimulating actions. The infusion of MSCs
into the suprarenal aorta following induction of AKI was not
associated with immediate adverse effects such as respiratory
distress, deterioration in renal function, or animal death.
Instead, as shown in Figure 1, MSC administration to rats
with severe AKI significantly protected renal function at 24 h
post-AKI and hastened functional recovery, whereas vehicle
or isogeneic fibroblast infusion had no beneficial effects on
outcomes.6,7,9 The fate of administered MSCs from male rats,
rats transgenic for human placental alkaline phosphatase,
MSCs loaded with various vital dyes, or iron sucrose
microparticles in kidneys, was monitored in all major organs
and the bone marrow using reverse transcriptase-polymerase
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Figure 1 | Treatment of severe acute renal failure (ARF) with syngeneic multipotent stromal cells (MSCs) or fibroblasts. (a) MSC
administration immediately after reflow to animals with severe ARF (Fisher 344 rats) significantly improves renal function at 24 h after
clamping, whereas vehicle- and fibroblast-treated animals show no such response. P¼ 0.002, vehicle- versus MSC-treated animals; P¼ 0.04,
fibroblast- versus MSC-treated animals; P¼ 0.05, vehicle- versus fibroblast-treated animals. (b) MSC administration significantly lowered
cortical and outer medullary injury scores. (c) MSC-treated rats showed significantly higher numbers of proliferating cells, whereas it
simultaneously reduced the number of apoptotic cells compared with controls. (d) PCNA, proliferating cell nuclear antigen; SCr, serum
creatinine; TUNEL, terminal transferase-mediated dUTP nick-end labeling. Reproduced from Togel et al.,6 with permission from the American
Physiological Society.
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chain reaction, in vivo two-photon laser confocal microscopy
(O’Brien Center, University of Indiana), magnetic imaging
resonance (University of Hamburg, Germany), immuno-
histochemistry, and in vivo tracking by bioluminescence
detection of firefly luciferase-transfected MSCs.20,21 Together,
these studies clearly demonstrated that the organ-protective
actions of infused MSCs were not mediated by early
differentiation and subsequent engraftment in the injured
kidney. Significantly, by 72 h post-AKI and MSC infusion, a
time point when renal function was approaching baseline,
although renal function in vehicle- or fibroblast-treated
animals continued to deteriorate, no MSCs were detectable in
kidneys and other organs. Very rarely, however, MSCs,
transgenic for human placental alkaline phosphatase, had by
day 7 intrarenally engrafted in an endothelial cell location,
and an occasional human placental alkaline phosphatase
transgenic MSC was detected by reverse transcriptase-
polymerase chain reaction in the bone marrow.8,9 The
significance of these low-level intrarenal engraftments
regarding recovery of renal function or fate in the bone
marrow is not known. Of importance, however, is our
observation that compared with vehicle-treated rats, at 1–3
months post-treatment of ischemia/reperfusion-induced AKI
with MSCs, renal function remained normal, interstitial
fibrosis was absent, and was associated with low expression
levels of profibrotic genes (plasminogen activator inhibitor
type I complexes, tissue inhibitors of metalloproteinase-1,
transforming growth factor-b, connective tissue growth
factor). In addition, MSC therapy prevented rarefaction of
the microvascular density in the kidney that was seen in
vehicle-treated animals. In these, there was progressive
deterioration of renal function, associated with microvascular
rarefaction, increased interstitial fibrosis, and upregulation of
profibrotic genes.9,13 MSCs delivered to and transiently
present in the injured kidney, are located primarily in
glomerular and in lesser numbers in peritubular capillaries.
Adhesion in the microvasculature is mediated by upregula-
tion of integrins and vascular cellular adhesion molecule-1
on both endothelial cells and MSCs.22 In addition, a fraction
of MSCs is able to attach via their CXCR4 receptors to
upregulated stromal-derived factor-1 in the injured kidney23
(see Togel et al., in this issue). When MSCs are adminis-
tered into the suprarenal aorta, as was done in all our
preclinical studies and in our Phase I Clinical Trial, no
ectopic differentiation of MSCs into adipocytes or other
mesenchymal cell types in the kidney or oncogenic transfor-
mation of administered cells is observed24 (see Kunter et al.,
in this issue).
Further investigation into the renoprotective- and regene-
ration-enhancing mediator mechanisms elicited by MSCs in
AKI showed that MSCs do not improve the early decrease in
renal blood flow, but that they exert powerful antiapop-
totic and mitogenic effects in the kidney, associated with
robust downregulation of proinflammatory cytokines (inter-
leukin-1b, tumor necrosis factor-a, interferon-g) and upre-
gulation of anti-inflammatory interleukin10 in renal cells.
Associated with these actions is upregulation of antiapoptotic
Bcl-2 and various growth factors such as basic fibroblast
growth factor, transforming growth factor-a, hepatocyte
growth factor, vascular endothelial growth factor, and others,
all known to mediate renoprotection and organ repair.6,13
Comparison of gene expression profiles between renoprotec-
tive MSCs and ineffective fibroblasts suggested that the
mix of growth factors delivered by MSCs into the kidney was
characterized by high expression levels of hepatocyte growth
factor, insulin-like growth factor-I, vascular endothelial
growth factor, stromal-derived factor-1, and other fac-
tors.11,13 The individual importance of insulin-like growth
factor-I in AKI therapy with MSCs was demonstrated by
Imberti and colleagues,12 and see Imberti et al., in this issue.
We have similarly shown that treatment of AKI with MSCs in
which vascular endothelial growth factor was knocked down,
using small interfering RNA technology, resulted in increased
post-AKI mortality compared with treatment with wild-type
MSCs, and resulted in significant rarefaction of the renal
microvasculature.9,13 Of additional importance in the use of
allogeneic MSCs in animal models, as well as in clinical
trials, is the fact that MSCs are hypoimmunogenic, suppress
T-cell responses, and exert broad based immune modula-
ting effects.11 These unique characteristics are due to the
fact that MSCs do not express blood group and major
histocompatibility complex-II antigens, as well as costimu-
latory factors, together making the use of allogeneic MSCs in
humans safe, as has been shown in numerous ongoing
clinical trials (http://www.clinicaltrials.gov; see Lange et al.,
in this issue).
In summary, the treatment of AKI in animals with
isogeneic or allogeneic MSCs provides for a safe and highly
effective intervention that is mediated by complex paracrine
and endocrine mechanisms that can, in part, be reproduced
by the intraperitoneal administration of MSC-conditioned
media.25 Together, the body of these preclinical data formed
the basis for our Phase I Clinical Trial, in which allogeneic
MSCs were administered to patients who were at high risk for
open-heart surgery-associated AKI.
PHASE I CLINICAL TRIAL: PREVENTION AND TREATMENT
OF AKI WITH ALLOGENEIC MSCs
In this safety and feasibility trial, adult subjects who have
undergone on-pump coronary artery bypass graft and/or
cardiac valve surgery were infused via the suprarenal aorta
with allogeneic MSCs, using a dose-escalating protocol. All
studied subjects presented with the following risk factors for
post-cardiac surgery-associated AKI: underlying chronic
kidney disease-1 to 4, congestive heart failure, diabetes
mellitus, hypertension, chronic obstructive pulmonary dis-
ease, and age 465 years.15–17,26 Preliminary analysis of the
outcomes in this cohort of study subjects showed that the
suprarenal, postoperative administration of allogeneic MSCs
is feasible and safe, as it has not resulted in adverse or serious
adverse events, and preliminary efficacy data appear promis-
ing, showing, compared with well-matched historical case
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controls from the same institution, that MSC therapy
prevented postoperative deterioration in renal function
(B20% AKI incidence in case controls), reduced length of
stay (by B40%), need for readmission (by B40%), and
prevented late deterioration in renal function, outcomes that
closely parallel those obtained in our preclinical studies. Of
note is the fact that these initial clinical observations provide
post hoc validation of the relevance of the experimental
models we used in our preclinical studies. After the comple-
tion of this Phase I trial, and if late safety is documented in all
studied subjects, a double-blind, controlled, multicenter
Phase II efficacy trial will be conducted.
In conclusion, the hypoimmunogenic and immune modu-
lating characteristics make the safe, off-the-shelf use of
allogeneic MSCs in patients possible and safe. The very short
time that MSCs remain in the acutely injured kidney and other
major organs, their paracrine and endocrine modes of action,
and the absence of their ectopic differentiation and oncogenic
transformation further underscore the safety of this novel from
of therapy. Although only limited or no published data are
currently available, Phase I/II clinical trails in which MSCs
are to be administered to kidney recipients from living,
unrelated donors, to patients with chronic allograft nephro-
pathy, and individuals with lupus nephritis, are currently being
conducted at the Organ Transplant Institute of China, Fuzhou
General Hospital. In addition, MSCs are tested for the treat-
ment of kidney transplant rejection at Leiden University,
The Netherlands (http://www.clinicaltrials.com).
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